Aventis and Regeneron Pharmaceuticals entered into an agreement to co-develop and commercialize Regeneron’s VEGF Trap. which is phase I clinical trials for treating solid tumor malignancies and non-Hodgkin’s lymphoma. The deal could be worth up to US$510 M to Regeneron.